Over-the-Counter Statins
Publication: Annals of Internal Medicine
Volume 142, Number 11
Abstract
In late 2004, the British government decided to allow a lipid-lowering agent to be sold as an over-the-counter medication. In contrast, the U.S. Food and Drug Administration recently decided not to do so. The United States and other countries will soon face similar decisions for other statins. Although statins have infrequent side effects and have been shown to be effective in moderate-risk primary prevention populations, many questions remain unanswered about their effectiveness at lower doses in over-the-counter use, the ability of patients to self-select themselves for appropriate therapy, and the social and economic implications associated with this method of distribution for preventive medications. A rational policy decision concerning over-the-counter statin use will require an effectiveness trial to provide data on how such drugs would be used in this context, as well as on the clinical outcomes that could be expected from this novel “route of administration.”
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Dyer O. FDA rejects sale of over the counter statins. BMJ. 2005;330:164. [PMID: 15661770]
2.
Associated Press. Over-the-counter cholesterol drug denied. CNN.com. 14 January 2005.
3.
Alvarez L. Britain to start direct sale of an anti-cholesterol drug. New York Times. 15 May 2004:A10.
4.
Reclassification summary for simvastatin POM to P. Medicines and Healthcare Products Regulatory Agency. 2003. Accessed at medicines.mhra.gov.uk on 31 May 2004.
5.
Melin JM, Struble WE, Tipping RW, Reynolds JM, Vassil TC, Levy SJ, et al. A Consumer Use Study of Over-The-Counter lovastatin (CUSTOM). Am J Cardiol. 2004;94:1243-8. [PMID: 15541238]
6.
Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419. [PMID: 12829553]
7.
Over-the-counter drug products. Center for Drug Evaluation and Research, Food and Drug Administration. 2005. Accessed at www.fda.gov/cder/Offices/OTC/default.htm on 27 January 2005.
8.
Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22. [PMID: 9613910]
9.
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007. [PMID: 12479764]
10.
Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-30. [PMID: 12457784]
11.
Brass EP. Consumer behavior in the setting of over-the-counter statin availability: lessons from the consumer use study of OTC Mevacor. Am J Cardiol. 2004;94:22F-29F. [PMID: 15519288]
12.
Consumer Behavior and Safety Data for the Non-prescription Mevacor 20 mg Joint Advisory Committee Meeting. U.S. Food and Drug Administration. 2004. Accessed at www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4086B1_02_N-FDA-TAB7.pdf on 26 January 2005.
13.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97. [PMID: 11368702]
14.
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7. [PMID: 7566020]
15.
Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58. [PMID: 12686036]
16.
Parks MH. Non-prescription Mevacor 20 mg Joint Advisory Committee Meeting. Background. U.S. Food and Drug Administration. 13-14 January 2005. Accessed at www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4086B1_02_C-FDA-TAB2.pdf on 26 January 2005.
17.
Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423. [PMID: 12829554]
18.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97. [PMID: 11368702]
19.
Shetty D. Mevacor Daily 20 mg Tablets Rx-to-OTC Switch. U.S. Food and Drug Administration. 13 January 2005. Accessed at www.fda.gov/ohrms/dockets/ac/05/slides/2005-4086S1_06_FDA-Shetty.pdf on 27 January 2005.
20.
Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-61. [PMID: 12132975]
21.
Kopjar B, Sales AE, Pineros SL, Sun H, Li YF, Hedeen AN. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol. 2003;92:1106-8. [PMID: 14583366]
22.
Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291:2344-50. [PMID: 15150206]
23.
Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-67. [PMID: 10695686]
24.
Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:1458-62. [PMID: 9600480]
25.
Ford ES, Giles WH, Mokdad AH. The distribution of 10-year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol. 2004;43:1791-6. [PMID: 15145101]
26.
Johnson LA. OTC status sought for statin drugs. CBSNews.com. 14 May 2004. Available at www.cbsnews.com/stories/2005/01/13/health/main666618.shtml.
27.
Marmot MG, Rose G, Shipley M, Hamilton PJ. Employment grade and coronary heart disease in British civil servants. J Epidemiol Community Health. 1978;32:244-9. [PMID: 744814]
28.
Alter DA, Iron K, Austin PC, Naylor CD. Socioeconomic status, service patterns, and perceptions of care among survivors of acute myocardial infarction in Canada. JAMA. 2004;291:1100-7. [PMID: 14996779]
29.
Mitka M. Are OTC statins ready for prime time? JAMA. 2004;292:317-8. [PMID: 15265834]
30.
OTC statins: a bad decision for public health [Editorial]. Lancet. 2004;363:1659. [PMID: 15158622]
31.
Avorn J. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York: Knopf; 2004.
32.
Schneeweiss S, Maclure M, Carleton B, Glynn RJ, Avorn J. Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. BMJ. 2004;328:560. [PMID: 14982865]
Information & Authors
Information
Published In
Annals of Internal Medicine
Volume 142 • Number 11 • 7 June 2005
Pages: 910 - 913
History
Published online: 7 June 2005
Published in issue: 7 June 2005
Keywords
- Biochemistry
- Cardiology and cardiovascular diseases
- Cardiovascular diseases
- Cholesterol
- Coronary heart disease
- Drugs
- Endocrinology
- Heart diseases
- Hospital medicine
- Hyperlipidemia
- Lipid disorders
- Lipids
- Lipoproteins
- Pathology and laboratory medicine
- Pharmacology
- Prevention, policy, and public health
- Proteins
- Public policy
- Research and reporting methods
- Toxicology
Copyright
© 2005 American College of Physicians.
Authors
Metrics & Citations
Metrics
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
Over-the-Counter Statins. Ann Intern Med.2005;142:910-913. [Epub 7 June 2005]. doi:10.7326/0003-4819-142-11-200506070-00009
Over-the-Counter Statins. Ann Intern Med.2005;142:910-913. [Epub 7 June 2005]. doi:10.7326/0003-4819-142-11-200506070-00009
View More
Get Access
Login Options:
Purchase
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
Create your Free Account
You will be redirected to acponline.org to create an account that will provide access to Annals.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.